BioMarin is a global biotechnology company that relentlessly pursues bold science to translate genetic discoveries into new medicines that advance the future of human health.
Since our founding in 1997, we have applied our scientific expertise in understanding the underlying causes of genetic conditions to create transformative medicines, using a number of treatment modalities.
Using our unparalleled expertise in genetics and molecular biology, we develop medicines for patients with significant unmet medical need. We enlist the best of the best – people with the right technical expertise and a relentless drive to solve real problems – and create an environment that empowers our teams to pursue bold, innovative science. With this distinctive approach to drug discovery, we’ve produced a diverse pipeline of commercial, clinical and preclinical candidates that have well-understood biology and provide an opportunity to be first-to-market or offer a substantial benefit over existing therapeutic options.
BioMarin has experienced substantial growth organically since its inception, primarily over the last decade. This steady growth in both cost structure and staff was essential to BioMarin’s emergence as a leading, fully integrated global biopharmaceutical company with approximately $2 billion in revenues from over 75 countries, a robust R&D pipeline, operating profits, and world-class technical capabilities through its 3,000 employees worldwide. As the company grows, BioMarin leadership desires to optimize the efficiency of its operations for the future through its next phase of growth.
BioMarin’s Technical Operations group is responsible for creating our drugs for use in clinical trials and for scaling production of those drugs for the commercial market. These individuals build and maintain BioMarin’s cutting-edge manufacturing processes and sites, provide quality assurance and quality control to ensure we meet regulatory standards, and procure the needed goods and services to support manufacturing and coordinating the worldwide movement of our drugs to patients.
In 2022, BioMarin launched its Enterprise Resource Planning (ERP) enterprise-wide operational initiative transforming the way we work by implementing an ERP system solution, SAP S4 HANA.
In Q1, 2025 our first five legal entities went live in SAP, the remaining entities will go live in Q1, 2026.
Implementing a new ERP impacts the entire company – putting this system in place is equally complex and transformational. The project team is built around the Global Process Workflows as outlined below:
The Global Process Owner (GPO) for each workflow is accountable for the development and integration of the workstream into the overall program and the Process Leads will report to them.
We are actively recruiting a Global Process Owner for Record to Report.
The Global Process Owner will be a role that requires a growth mindset and dynamic set of business and collaboration skills, including the following:
An Equal Opportunity Employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, or protected veteran status and will not be discriminated against on the basis of disability.